HOLX's BCI test gains traction as new SABCS studies are set to highlight its growing role in guiding extended endocrine therapy decisions.
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
| - Industry | - Sector | Stephen P. MacMillan CEO | XFRA Exchange | US4364401012 ISIN |
| US Country | 7,063 Employees | - Last Dividend | 3 Apr 2008 Last Split | 21 Jun 1990 IPO Date |
Hologic, Inc. is a pioneering company focused on improving women’s health through early detection and treatment, leveraging advanced diagnostics, medical imaging systems, and surgical products. Founded in 1985 with its headquarters in Marlborough, Massachusetts, Hologic operates across four distinct segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Its commitment to innovation and improving patient outcomes positions Hologic as a leader in the healthcare industry, ensuring it meets the diverse needs of healthcare providers and patients alike.